Get the latest news, insights, and market updates on RVMD (Revolution Medicines, Inc.). Explore the news page 3 on MyTopStock.com for investor discussions, analysis, and real-time stock performance coverage.
Revolution Medicines Awarded Voucher for Daraxonrasib (RMC-6236) Under FDA Commissioner's National Priority Voucher Pilot Program
REDWOOD CITY, Calif., Oct. 16, 2025 (GLOBE NEWSWIRE) -- Revolution Medicines, Inc. (Nasdaq: RVMD), a late-stage clinical oncology company developing targeted therapies for patients with RAS-addicted cancers, today announced that the U.S. Food and Drug Administration (FDA) has granted a non-transferrable voucher for daraxonrasib (RMC-6236), the company’s RAS(ON) multi-selective inhibitor, under the Commissioner's National Priority Voucher (CNPV) pilot program. Daraxonrasib is being studied in two Oct 17, 2025 - $RVMD
Did Leadership Moves Just Shift Revolution Medicines' (RVMD) Investment Narrative Ahead of Key Launches?
Revolution Medicines recently appointed Dr. Alan Sandler as chief development officer, along with new general managers for the U.S. and Europe, in moves aimed at strengthening its clinical and commercial operations ahead of potential product launches. This leadership enhancement highlights the company’s focus on advancing its pipeline of targeted cancer therapies, particularly as it prepares for possible regulatory milestones and market expansion. We'll explore how bolstering clinical and... Oct 7, 2025 - $RVMD
Assessing Revolution Medicines After Recent Cancer Breakthrough and 15% Monthly Rally
Trying to figure out what to do with Revolution Medicines stock? You are not alone, especially with all the buzz surrounding biotech stocks lately. Over the past month, Revolution Medicines has climbed an impressive 15.3%, and it has grown 6.2% so far this year. Looking long term, the stock is up a massive 156.6% in the last three years, showing real staying power despite a small slip of -1.3% over the last 12 months. Much of this movement seems tied to recent optimism in the cancer... Oct 6, 2025 - $RVMD
Revolution Medicines, Inc. (RVMD) Insider Sells Shares
Revolution Medicines, Inc. (NASDAQ:RVMD) is among the most promising biotech stocks to buy according to hedge funds. On September 24, 2025, General Counsel and Officer of Revolution Medicines, Inc. (NASDAQ:RVMD), Jeff Cislini, offloaded 1,799 shares of common stock, priced at $44.26 per share. This transaction of $79,623 leaves the ownership of Cislini to 50,425 shares […] Oct 2, 2025 - $RVMD
We use cookies and similar technologies to collect and process data such as browsing activity or unique identifiers.
Selecting "Allow All" to help us understand site usage and improve the platform.
Choosing "Essential Cookies Only" enables only the cookies necessary for core site functions, such as staying logged in.
For more information, please see our Privacy Policy.
Continue with Google
Continue with Facebook
Continue with Microsoft
Continue with Apple